Tiziana's Foralumab Hits Goals in MS Phase 2 Trial
Tiziana Life Sciences announced positive results from a phase 2 trial of Foralumab in secondary progressive multiple sclerosis. The trial met primary endpoints, showing reduced neuroinflammation and safety. Secondary endpoints, including fatigue and EDSS scores, also showed statistical significance. The company plans to advance the 50 microgram dose in future studies.





